Abortion

Nine months ahead of the first presidential primary of the 2024 election season, many voters, especially women, say candidates’ views on abortion will again be a key issue, and Democrats hold a strong edge over Republicans on the issue, a new KFF Health Tracking Poll finds.Three in 10 registered voters…

Nearly a year after the Supreme Court overturned Roe v. Wade, this poll examines the public’s views of abortion and the Supreme Court, and knowledge about mifepristone, a medication abortion drug that is the subject of another court case, the ACA’s preventive services provision and HIV in the US.

This factsheet provides an overview of medication abortion, with a focus on federal and state regulations pertaining to its provision and coverage, and the role of the drug in self-managed abortions.

A new KFF analysis reviews exceptions to abortion bans and describes how the stated aim to provide life-saving and health-preserving abortion care may not be achieved in practice. Abortion is currently banned in 14 states and many other states have attempted to ban or severely restrict abortion access. Exceptions to…

This issue brief examines the varying exceptions (for life, health, rape/incest, and fatal fetal anomalies) in state abortion bans and restrictions and the complications that arise when pregnant people attempt to access abortion care under these exceptions.

This report answers some key questions about abortion in the United States and presents data collected before and after the overturn of Roe v. Wade.

This policy watch explains the April 21, 2023 United States Supreme Court’s ruling on Alliance for Hippocratic Medicine v. FDA, a case challening the FDA’s approval of mifepristone, the medication abortion pill.

This policy watch explains the two conflicting rulings on the provision of mifepristone issued by two separate District Courts on April 7, 2023, Alliance for Hippocratic Medicine v. FDA and State of Washington v. United States Food and Drug Administration.